28 November 2023
SHARE NOW
ATE
Cell Therapy
CMC
Gene Therapy
In this interview filmed at Advanced Therapies Europe 2023, David Sourdive discusses challenges in manufacturing science and technology specifically in the cell and gene therapy industry.
David Sourdive, Executive Vice President CMC & Manufacturing at Cellectis joins us for this interview to explore the challenges of manufacturing science and technology (MSAT), such as analytics, as well as the potential complexities in the processes of advancing MSAT for commercial production.
To watch more on the topic of MSAT with David, watch the session here >>
More like this
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies
We caught up with Patrick M Gailliot, Sr. Director, Patient Operations at Abeona Therapeutics, to talk to him about why his work gives him so much joy, preview his session at Advanced Therapies Week in Dallas, and explain the value he gets from the event.
26 November 2024
Texas Cell and Gene Manufacturing Landscape
Ahead of Advanced Therapies Week 2025 in Dallas, we take a look at the Texas cell and gene manufacturing landscape.
19 November 2024
